Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives

Hamid Rashidzadeh‡,1,2, Hossein Danafar‡,1,2,3, Hossein Rahimi2, Faezeh Mozafari2, Marziyeh Salehiabar3, Mohammad Amin Rahmati2, Samaneh Rahamooz-Haghighi4, Navid Mousazadeh4, Ali Mohammadi2, Yavuz Nuri Ertas6,7, Ali Ramazani1, Irada Huseynova8, Rovshan Khalilov3,9,14, Soodehbeh Davaran3,4, Thomas J Webster11, Taras Kavetskyy*,3,12,13, Aziz Eftekhari**,10,12,14, Hamed Nosrati***,2,3,16, Navi Mousazadeh4,10,12,14 & Mehdi Mirsaeidi****,16

1Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
2Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
3Joint Ukraine-Azerbaijan International Research & Education Center of Nanobiotechnology & Functional Nanosystems, Drohobych, Ukraine, Baku, Azerbaijan
4Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51656-65811, Iran
5Department of Plant Production & Genetics, Faculty of Agriculture, University of Zanjan, Zanjan, Iran
6Department of Biomedical Engineering, Erciyes University, Kayseri 38039, Turkey
7ERNAM-Nanotechnology Research & Application Center, Erciyes University, Kayseri 38039, Turkey
8Institute of Molecular Biology & Biotechnologies, Azerbaijan National Academy of Sciences, 11 Izzat Nabiyyev, Baku AZ 1073, Azerbaijan
9Department of Biophysics & Biochemistry, Baku State University, Baku, Azerbaijan
10Maragheh University of Medical Sciences, Maragheh 78151-55158, Iran
11Department of Chemical Engineering, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA
12Department of Surface Engineering, The John Paul II Catholic University of Lublin, 20-950 Lublin, Poland
13Drohobych Ivan Franko State Pedagogical University, 82100 Drohobych, Ukraine
14Russian Institute for Advanced Study, Moscow State Pedagogical University, 1/1, Malaya Pirogovskaya St, Moscow 119991, Russian Federation
15Polymer Institute of SAS, Dúbravská cesta 9, Bratislava 845 41, Slovakia
16Department of Public Health Sciences, University of Miami, Miami, FL 33146, USA
*Author for correspondence: kavetskyy@yahoo.com
**Author for correspondence: ftekhrani@gmail.com
***Author for correspondence: nosrati.hamed2020@gmail.com
****Author for correspondence: msm249@med.miami.edu
‡Authors contributed equally

Coronavirus 2019 (COVID-19), as an emerging infectious disease, has caused significant mortality and morbidity along with socioeconomic impact. No effective treatment or vaccine has been approved yet for this pandemic disease. Cutting-edge tools, especially nanotechnology, should be strongly considered to tackle this virus. This review aims to propose several strategies to design and fabricate effective diagnostic and therapeutic agents against COVID-19 by the aid of nanotechnology. Polymeric, inorganic self-assembling materials and peptide-based nanoparticles are promising tools for battling COVID-19 as well as its rapid diagnosis. This review summarizes all of the exciting advances nanomaterials are making toward COVID-19 prevention, diagnosis and therapy.

Lay abstract: The emergence of the new coronavirus 2019 (COVID-19) has affected millions of people around the world and has become a serious threat to human life. To date, nanotechnology-based tools have been effective in preclinical studies against a variety of pathogens, including respiratory viruses, herpes virus, human papillomavirus and HIV. Nanoparticles, particles smaller than a micrometer, have drawn particular interest in the management of COVID-19 disease due to their unique properties (easy preparation, low cost, easy modification, appropriate size, etc). Nanotechnology-based strategies for COVID-19 disease management include the development of tools for rapid, accurate and sensitive diagnosis, pro-
duction of effective disinfectants, delivery of mRNA vaccines into human cells and delivery of antiviral agents into the body.

First draft submitted: 27 November 2020; Accepted for publication: 10 February 2021; Published online: 8 March 2021

Keywords: coronavirus • COVID-19 • diagnosis • nanotechnology • SARS-CoV-2 • treatment

The new coronavirus 2019 (COVID-19) outbreak, which emerged in Wuhan, China, has infected millions of people worldwide and has become a global threat [1]. COVID-19 is rapidly spreading, causing the deaths of large numbers of people worldwide, and the death rate has been exponentially increasing [2]. Coronaviruses are a group of enveloped viruses with a single-stranded RNA genome approximately 26–32 kb in size that infect not only humans but also animals, including birds and mammals [3–5]. Rapid mutation, altered tissue tropism, cross-species transmission and adaptation to various epidemiological conditions are the main characteristics of this group of viruses [6]. This group of viruses is the largest group of viruses belonging to the Nidovirales order, Coronavirinae suborder and Coronaviridae family. The Coronaviridae family includes two subfamilies: Letovirinae (Alphacoronavirus) and Orthocoronavirinae (Alphacoronavirus [αCoV], Betacoronavirus [βCoV], Gammacoronavirus [γCoV] and Deltacoronavirus [δCoV]) [7,8]. Human coronaviruses first were identified in the 1960s and so far there have been six types identified. Four types, including OC43, 229E, NL63 and HKU1 cause the common cold and gastrointestinal infections and the other two include the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus with high morbidity and mortality which have attracted a lot of attention and have caused great concern [9].

The causative agent of COVID-19, named SARS-CoV-2, has a 96.3, 89 and 82% nucleotide similarity to bat CoV RaTG13, SARS-like CoV ZXC21 and SARS-CoV, respectively, confirming its zoonotic origin [10–13]. Generally, physical contact, airborne droplets and fomites are common ways of transmitting respiratory diseases such as COVID-19. The transmission of the infection via physical contact refers to the direct transmission of the infection from an infected person to the next and fomites refer to the indirect transmission of the infection through intermediate objects [14]. Fever, cough and tiredness are the main symptoms and shortness of breath, headache, anorexia, sore throat, vomiting, diarrhea, abdominal pain, panting and rhinorrhea are the less common symptoms of COVID-19. Moreover, the severity of the disease may vary if underlying diseases such as elevated blood pressure, diabetes and coronary heart disease are present [12,15]. A high viral load in the upper respiratory tract and also because many people with COVID-19 are asymptomatic has resulted in high COVID-19 transmission between persons [16].

SARS-CoV-2 contains four structural proteins including spike (S), membrane (M), nucleocapsid (N) and envelope (E) proteins. S protein with a molecular weight of 250 kDa is found on the virus surface and involved in corona formation (Figure 1) [17–19]. SARS-CoV-2 enters via the S protein into the host cells and replicates its genome within the host cells. Actually, the main stage in pathogenesis by SARS-CoV-2 is the entry of SARS-CoV-2 into host cells, which begins by binding to a specific receptor on the surface of host cells and then entering the endosome and eventually fusing the lysosomal and viral membranes [20,21]. Suppressing the activity of the S protein is one way to treat the SARS-CoV-2 disease which can block the virus [22,23]. The N protein possessing a molecular weight of 43–50 kDa is the only protein among the structural proteins of SARS-CoV-2 whose core role is to bind to the virus genome with several amino acids, lysine and arginine, and to form nucleocapsids [24,25]. The transient expression of the N protein has been shown to significantly increase the production of viral-like particles (VLPs), suggesting that it may be involved in the formation of a complete virion rather than a viral envelope [26–28]. The M protein, possessing a molecular weight of 25–35 kDa, is a transmembrane glycoprotein type III and is the most abundant protein on the surface of the virus [29]. This protein is the main organizer of virus assembly and interacts with other structural proteins [29]. Binding M and N proteins together stabilize both the nucleocapsid and the virion’s inner nucleus, which eventually completes the viral assembly [30–32]. Among the structural proteins of SARS-CoV-2, the E protein is the smallest protein with a molecular weight of 10–74 kDa. The E protein is abundantly expressed within infected cells during the proliferation cycle, however, a small proportion is incorporated into the virion envelope [33,34]. In addition to the structural proteins encoding genes, specific regions of the virus genome have been identified which encode proteins required for viral replication, including papain-like protease (PLpro) and coronavirus main protease (3CLpro) [35]. The early diagnosis of the disease would lead to early measures and hence...
effective management of the disease due to the extremely rapid spreading of COVID-19 between persons. The availability of the entire SARS-CoV-2 genome sequence has enabled researchers to design and develop PCR kits for the detection of COVID-19. Currently, the diagnostic kits used for the diagnosis of COVID-19 are based on the diagnosis of the SARS-CoV-2 nucleic acid (quantitative reverse transcription PCR [RT-qPCR]) [36]. This approach faces challenges such as limited access to the required equipment and reagents, necessity of skilled personnel, potential false negative results and time consuming procedures [37].

To date, platforms based on nanotechnology have been effective in preclinical studies toward viral pathogens including such respiratory viruses, herpes simplex, human papillomavirus and HIV [38,39]. Nanotechnology-based techniques can be used to combat COVID-19 pandemics in different ways including development of a sensitive, rapid and specific diagnostic tool for COVID-19, the use of nanomaterials to deliver antiviral agents, improving contact tracing tools, coating of nanomaterial surfaces to inactivate the virus and preparing effective environmental disinfectants [40]. Antiviral agents interfere at certain stages of the virus replication cycle to prevent them from occurring, unlike vaccines which are used to boost the human immune system [41]. Nanomaterials are capable of changing the pharmacokinetic properties of the encapsulated drug and via controlled release mechanism, they can reduce the required concentration of drug. Moreover, the antiviral effects of the established nano-drug can be improved by binding a specific ligand to the surface of the nanoparticle containing the drug for recognition of molecular components of the target tissue/organ [42].

Surprisingly, nanomaterials can create effective interactions between the analyte and the sensor owing to their large surface-to-volume ratios, allowing fast and accurate virus detection [43]. Nanotechnology can improve targeting virus molecules on biological fluids such as nasal, throat and blood samples. Specific virus receptors can be decorated on the surface of magnetic nanomaterials. Since viruses are nanoparticles, virus properties may be used to design virus-like structures to provide targeted drug delivery and gene modifications.

There are concerns such as cargo degradation, no bioavailability or rapid clearance with regard to the delivery of drugs, genes and proteins to the patient's body, which nanomedicine can address by providing nanoparticle based carriers [44,45]. Different kinds of nanomaterials (such as inorganic, lipid and polymer based nanoparticles) with high loading capacity and unique properties can be used to encapsulate and deliver protein cargos efficiently [46,47]. Intranasal delivery of polymer encapsulated antigens causes a strong immune response and vaccination success relies on polymer type used in combination with the antigen [48,49]. It has been proposed that lipid-based nanostructures could be used to deliver mRNAs or siRNAs to generate viral proteins or vaccination or to deactivate viral target genes [50].

Nanotechnology can also improve the vaccine development. Currently, the most promising vaccines for COVID-19 are made of mRNA from surface proteins of SARS-CoV-2 and encapsulated in nanoliposomes with specific physicochemical properties [51]. Since COVID-19 is transmitted through respiratory droplets and direct contact, disinfecting the air, skin or surrounding surfaces are important preventive measures [52]. Despite the effectiveness of chemical disinfectants in disinfecting air and contaminated surfaces, they face problems such as the need for higher concentrations to completely suppress the virus, insufficient efficiency over time and possible threats to public health and the environment [53–55]. Metal nanoparticles such as silver, copper and titanium dioxide are alternatives to currently used chemical disinfectants with unique antiviral activities, durability and efficacy in low concentrations [56]. These metal nanoparticles with photo-dynamic and photo-thermal capabilities can be used for COVID-19.
Nanotechnology-based treatments for COVID-19 infections

Currently, the US FDA has only approved remdesivir for COVID-19, but no vaccines at this point. Therefore, the development of novel and effective strategies is highly demanded and one promising approach is to mitigate this disease through the use of nanotechnology [57].

It has been suggested that nanotechnology-based vaccines or monoclonal antibodies will be a promising approach for effective treatment and quick diagnosis. The development of novel nano-therapeutic materials for improving the efficacy of treatment of COVID-19 could be based on following strategies: fabrication of polymeric nanoparticles with rapid and high mucus penetration features, development of biodegradable, nontoxic and stable nanoparticles which are intended to be implemented in the lung with minimum pulmonary toxicity during treatment and surface modification of the nanoparticles by conjugation of PEG as a capping agent and targeting moieties to minimize adverse effects and effective therapy.

A list of nanostructured materials with active and effective antiviral activities is shown in Figure 2.

Polymeric-based nanostructured materials

Polymeric based nanostructured materials may be a powerful tool in fighting against COVID-19. They have acceptable safety profiles, good biocompatibility and biodegradability, feasible synthetic protocols, prevent degradation of encapsulated drugs and the capability of being simply modified into preferred shapes and sizes and tunable properties [58–60]. Poly (lactic-co-glycolic acid) (PLGA) and PEG are FDA approved polymers which can be employed against COVID-19. This is because of their outstanding biocompatibility and biodegradability when introduced into the human body [61–63]. Although polymeric nanoparticles are useful tools for drug delivery, they are rapidly taken up by the reticuloendothelial system. In order to overcome the aforementioned drawback, surface modification by PEG is needed [64]. For example, Sankarakumar et al. developed polymeric virus catchers using molecular imprinting technique as a cost-effective, more stable, rapid and safe mode of anti-viral therapy (Figure 3) [65].

Lin et al. fabricated a novel nanovaccine based on synthetic biodegradable PLGA and DEPE-PEG polymers to deliver subunit viral antigens and STING agonists and an adjuvant in a virus-like fashion as a safe and effective prophylactic measures against Middle East Respiratory Syndrome Coronavirus (Figure 4). The developed capsid-like hollow nanostructured polymer possessed multiple precious and favorable properties such as lowering systemic reactogenecity, pH-responsive release profile and prominent local immune activation. Through the conjugation of antigens, nanoparticles bear a very close resemblance to native virions in morphological properties and co-delivery of both STING agonists and antigens can significantly promote immune potentiation as illustrated in Figure 4. The results indicated that this strategy facilitated an accelerated development of safe and effective vaccines in battling with emerging viral pathogens [66].
Nanotechnology against the novel coronavirus (SARS-CoV-2) Review

Figure 3. Schematic illustration of polymeric virus catchers fabricated using molecular imprinting techniques. Reproduced with permission from [65] licensed with CC BY 3.0.

Figure 4. Hollow nanoparticles against coronavirus disease-19. (A) Fabrication of a nanovaccine based on synthetic biodegradable PLGA and DEPE-PEG polymers using a double emulsion technique. (B, C) Cryo-electron microscopy of cdGMP-loaded hollow nanoparticles. (D) Determination of the size distribution of nanoparticles via dynamic light scattering. HPLC diagram of adjuvant-loaded nanoparticles (NP[cdGMP]) and soluble cdGMP. (E) HPLC diagram of soluble cdGMP and adjuvant-loaded nanoparticles (NP[cdGMP]). (F) Calibration curve for the determination of cdGMP encapsulation efficiency. (G) cdGMP release profiles at pH 5 and pH 7. PLGA: Poly (lactic-co-glycolic acid). Reproduced with permission from [66] © WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim (2019).
Self-assembling protein based nanoparticles

A novel group of nanoparticles has been produced via oligomerization of monomeric proteins, in which its building blocks were obtained by recombinant technologies, also in the formation of Self-Assembling Proteins based Nanoparticles (SANPs) which possess multiple biomedical applications [67]. The production of SANPs in the range of a virus size (20–100 nm) makes them propitious candidates for the generation of a nanovaccine against respiratory viruses [68]. Roux et al. developed SANPs based on nucleoprotein (N) from the respiratory syncytial virus (RSV) nucleocapsid and explored it as a potential vaccine antigen in the RSV mouse model. They found that the vaccinated mice were predominantly protected against RSV replication and lower viral load in the lungs. Mucosal immunization with fabricated nanovaccines elicited both systemic and local immunity with high titers of IgA anti-N antibodies, IgG2a and IgG1, antigen-specific CD8+ and CD4+ T cells [69]. Louis et al. modified the nanovaccine by adding the palivizumab-targeted epitope (called FsII) to the N protein and formed a potential nanovaccine with enhanced immune response against RSV. They also found that the load of RSV in the lungs of challenged mice were significantly reduced [70]. VLPs are supramolecular assemblies with diameters ranging from 20 to 200 nm, spherical in shape and generated from the self-assembly of viral capsid proteins. Although VLPs have no viral genetic materials, they can be considered as a potential tool for vaccine production since they have advantages of impeccably mimicking the antigenic epitopes and structure of their corresponding native viruses. Hence, the presence of successive antigens on a particle’s surface (antigen-bearing particles) can promote efficient phagocytosis by antigen-presenting cells and subsequent activation [71,72].

Recently, Lee et al. revealed that the administration of VLPs containing multiple ectodomains of matrix protein 2 (M2e5x VLP) of influenza virus by an intranasal route could induce both humoral and cellular immune responses. Intranasal vaccination of the developed vaccine lowered viral loads [73].

Peptide-based nanoparticles

Studies have reported that mutations of amino acids and short peptide inhibitors (SPI) are promising tools against infections associated with SARS-CoV [74]. The development of vaccines based on peptides which could express the C-terminal heptad repeat region, in a trimeric coil conformation stage, would be an ideal therapeutic approach for the treatment of SARS-CoV associated infections and this strategy is established by employing peptide-based nanoparticles (PBNPs) [75]. More recently, Han and colleagues designed and simulated peptide inhibitors against COVID-19. They prepared peptide inhibitors (PI1–4) extracted from angiotensin-converting enzyme 2 (ACE2) which acts as a highly promising tool to block the COVID-19 receptor binding domains. PI 1 is inclusive of α1 (residues 21 to 55), PI 2 is inclusive of α1, α2 and the loose chain between β3 and β4 (residues 21–88 and 349–357), PI 3 is inclusive of α1, α2 and β3, β4 (residues 21–105 and 323–362) and the composition of PI 4 was similar with PI 3 but different linkage (residues 21–95 and 335–400). In the initial effort to block COVID-19, SPIs were investigated and amino acid mutations were employed to the S protein of SARS-CoV, but SPIs shortly kept their secondary structures. For multivalent binding and blocking of the COVID-19 receptors, successive peptides should be conjugated to the surfaces of nanostructured materials. It is achievable by utilizing the PBNPs which potentially neutralized COVID-19 infections [76]. Recently, an SPI extracted from ACE2 provided noteworthy traces for blocking of COVID-19. Additionally, it was demonstrated that the binding efficacy can be promoted by providing multiple binding of SPI onto the nanocarriers [77,78].

Inorganic & metal nanoparticles

Inorganic nanoparticles exhibit a broad range of applications in the medical filed [79,80]. Their attractive features such as biocompatibility, ease of synthesis, controllable size and unique optical and physiochemical properties make them suitable for biological applications. This group of nanoparticles include a complex hybrid of materials in which its core is made of inorganic agents while its outer shell is composed of organic moieties [81,82]. Among the inorganic nanoparticles, gold nanoparticles (AuNPs) are ideal for vaccine development, because these nanoparticles are readily internalized via both dendritic cells and macrophages, leading to their activation [83,84].

The production of AuNPs is possible because of their easy production in large-scale and with desired particle sizes, they can also be readily functionalized due to the strong affinity between thiol groups and gold [85–87]. Additionally, inert carriers, like AuNPs, do not elicit any immune response [88]. Hence, AuNPs are an appealing platform for the development of nanovaccines by antigen functionalization [89]. Several moieties, such as antigens and adjuvants, can be attached at high density on AuNPs, leading to enhanced antigen presentation and immunogenicity [90,91]. These nanoparticles can be employed for intranasal administration as they can be carried into the lymph nodes,
Influenza virus

Inactivation

PoGNP-virus interaction occurs

Inhibition of infection

PoGNP: Porous gold nanoparticle.

Figure 5. Inactivation of influenza A virus treated with porous gold nanoparticles. PoGNP interacts with Influenza A virus surface proteins and cleaves their disulfide bonds. Inactivated viruses exhibit lower infectivity to cells.

resulting in triggering a robust antigen specific cytotoxic T-cell immune response \[92,93\]. For example, Sekimukai et al. evaluated two types of vaccine adjuvants, based on Toll-like receptor (TLR) agonists and AuNPs, against COVID-19 infections \[94\]. These two adjuvants already have proven their roles in vaccine engineering and AuNPs, and the antigen carriers as agonists of TLR have been used for developing an ultraviolet-inactivated SARS-CoV vaccine.

The AuNP-adjuvanted protein could induce a strong IgG response, but causes a highly allergic inflammatory response. However, a TLR agonist-adjuvanted vaccine could successfully induce protective antibodies without a Th1/17 cytokine response and eosinophilic infiltration. Li and colleagues developed a novel subunit vaccine based on AuNPs and the E2 protein against the recombinant classical swine fever virus E2 protein (CSFV E2). The E2 protein was successfully conjugated to AuNPs to generate stable particle complexes called E2–AuNPs. According to their \textit{in vitro} results, the E2–AuNPs complex exhibited the same immunogenicity as the E2 protein, also AuNPs can enhance the phagocytosis of E2 proteins via antigen-presenting cells. In addition, \textit{in vivo} study showed that the IFN-\( \gamma \) and IL-10 cytokines, lymphocyte proliferation index and titer of antibody induced by the developed E2–AuNPs were relatively high in comparison with AuNPs or the E2 group. Their findings indicated the potential of employing AuNPs as a vehicle to improve the body’s immune response for fabricating subunits vaccines against CSFV E2. Also this platform can be applied to the development of other flavivirus subunit vaccines like the bovine viral diarrhea virus and hepatitis C virus \[95\]. Kim et al. developed porous gold nanoparticles (PoGNPs) to bind disulfide bonds through gold–thiol interactions against Influenza A virus (Figure 5). The fabricated PoGNPs could predominantly reduce viral infectivity of various Influenza virus strains (H1N1, H3N2 and H9N2). Furthermore,
reverse transcription polymerase chain reaction results confirmed that the PoGNPs hampered the fusion of the viral membrane via blocking the entry route of virus through deformation in the conformational of hemagglutinin [96].

**Role of nanotechnology in vaccine development**

Generally, nanovaccines are a new generation of vaccines that use nanoparticles to deliver antigens into the human body. Since nanoparticles are in the same size scale as the viral particles, they could effectively enter into the cell and lead to the expression of antigens from the delivered gene construct (DNA or mRNA vaccines) or directly target the immune cells for the delivery of antigens. Through strategies such as oral and intranasal, as well as intramuscular and subcutaneous injections, nanoparticles can be administered to bypass tissue barriers and can target key areas such as lymph nodes [97–100]. Humoral and cellular immunity have been shown to play a protective role in SARS CoV infection [101,102]. Nanoparticles are capable of targeting both adaptive (T cells, B cells) and innate (macrophages, monocytes and neutrophils) immune systems at the cellular level. The ability to deliver molecular adjuvants, as well as possessing intrinsic adjuvant property in some cases for the loaded antigens, is one of the advantages of nanoparticles in increasing the efficacy and safety of the vaccine. Adjuvants enable the cell to easily recognize and respond to antigens by catalyzing the immune response. Physicochemical properties of antigen, target areas, biological stability and the amount of required immunogen release are factors involved in antigen loading inside or on the nanoparticle surface. The physical loading of antigens on nanomaterials relies on its surface charge as well as noncovalent hydrophobic interactions [103,104]. Currently, many vaccine companies encapsulate the gene material, protein/peptide of the vaccine in nanoparticles such as lipid nanoparticles (LNPs). For example, COVID-19 mRNA-based vaccines made by BioNTech/Pfizer and Moderna are encapsulated in LNPs. The mRNA vaccine encapsulated in positively charged LNPs is highly stable and resistant to RNase-mediated degradation and forms self-assembled particles that can be injected in various routes. LNPs are synthesized by self-assembly of an ionizable cationic lipid and due to their similar size to viruses (80–200 nm), they can efficiently deliver mRNA into the cytoplasm [105,106]. Modifications of these nanoparticles with cholesterol or PEG, different LNPs can be developed. It is worth to mention that cholesterol and the PEG-lipid composition could increase stability and half-life of the formulation, respectively. By entry of the LNPs-mRNA vaccine complex into the cell through endocytosis mechanism, endosomal escape is facilitated due to the presence of lipid in composition of LNPs and then it releases mRNA into the cytoplasm, where the mRNA is translated into antigenic proteins that stimulate the immune system which results in the formation of neutralizing antibodies [107–109]. In addition to LNPs, several nanoparticles have been utilized as propitious vehicles for mRNA delivery, such as cationic polymer nanoparticles, polyethyleneimine, oil-in-water (O/W) cationic nanoemulsion and PEG-lipid functionalized dendrimer nanoparticles [103,110].

**Nanomaterial applications in diagnosing COVID-19**

Among the above mentioned nanostructured materials, most metallic nanoparticles are intended to be utilized for diagnostic purposes rather than therapy. An accurate, rapid and early diagnosis of COVID-19 is critically important as it can: improve the therapeutic efficacy and effectiveness of the treatment resulting in the avoidance of long-term complications for patients, ascertain areas with increased incidence of infections and help public health officials to monitor the spread of the virus and prognosticate what surge capacity would be needed in infected areas [111]. The WHO and other organizations have concluded that a rapid diagnostic tool is needed in order to end this pandemic. Current screening and diagnosing tests for COVID-19 infection is based on chest computed tomography and rtPCR, respectively [112,113]. Moitra et al. fabricated the selective naked-eye detection of COVID-19 based on AuNPs capped with antisense oligonucleotides which can diagnose and detect the number of positive COVID-19 cases from isolated RNA specimens within just 10 min without requiring any advanced instrumental facilities and equipment. The thiol modified antisense oligonucleotides capped AuNPs through gold–thiol interactions could agglomerate selectively in the presence of the corresponding RNA sequence of COVID-19 and then its surface plasmon resonance would undergo changes. Further, by introducing RNaseH, the RNA strand is liberated from the RNA-DNA hybrid, resulting in a visually detectable precipitate [114].

Zhu and colleagues successfully developed a one-step reverse transcription loop-mediated isothermal amplification (RT-LAMP) coupled with nanoparticle-based biosensors (NBS) (RT-LAMP-NBS) for accurate and rapid diagnosing of COVID-19 in a single tube reaction. The sensitivity of the fabricated diagnostic system was 12 copies per reaction and without any generation of any cross-reactivity from non-COVID-19 templates. For patients diagnosed by COVID-19, the sensitivity of the developed RT-LAMP-NBS was 100% (33/33) in oropharynx swab samples and its specificity for non-COVID-19 patients was also 100% (96/96). All steps from the sample collection
up to the interpretation of the final test result takes only 1 h [115]. Furthermore, nanoparticle-based tools against respiratory viruses are summarized in Table 1.

**Unsolved concerns**

Despite the global efforts to perceive the specific treatment approaches for COVID-19, various concerns still remain unsolved. COVID-19, which is generated from RNA viruses, are prone to genetic recombination and mutation, thus, it will be considered as a serious global health threat in the future. In the most optimistic condition, the first anti-COVID-19 vaccine would be available in the market during 2020–2021, due to the requirements of large-scale production as well as lengthy and strict regulatory affairs, but until then, all efforts must be done to discover a drastic treatment approach so as to face this respiratory infectious diseases. Recently, a great number of efforts have been made by R&D employees at many pharmaceutical industries as well as researchers and scientists on exploring the applicable anti-virus formulation from the old fashioned drugs or newer ones and vaccine development. Overall, the profound role of nanotechnology and nanoscience is undeniable, but these propitious materials could cause severe issues in lung and respiratory systems. The five main patho-biological aspects are as follows: cell toxicity, fibrosis, inflammation, oxidative stress, genotoxicity and immunotoxicity which must be considered when using nanoparticles or associated approaches for treating current and future coronavirus infections.

**Future possible strategies to tackle COVID-19 by means of nanotechnology**

The development of effective nanomedicines against COVID-19 is based on the following approaches; capability of nano-vehicles to bypass the conventional limitations of antiviral therapeutics, co-delivery or combination drug therapeutics by means of nano-vehicles, active targeting by the conjugation of (nano) targeting moieties on the surfaces of nano-vehicles, development of nano-biosensors for rapid detection, anti-viral surface coatings via nanomaterials as a major prevention goal, as well as incorporation of nanomaterials with anti-viral properties into facial masks, gloves and other contaminated surfaces, capability of nanomaterials as disinfectant tools to inactivate or kill the pathogenic microorganisms and vaccine development using nanomaterials and chemically alter/(re)engineer drugs to improve the compatibility of drugs with a particular type or class of nano-vehicles – a generic approach for therapeutics candidates with similar physiochemical properties [134,135].

There is a significant genomic match between COVID-19 and other coronaviruses, therefore, it is valuable to revisit these strategies along with nanotechnology to tackle COVID-19 [136]. Some of the antiviral therapeutics and their water solubility, clinical trial phases and log p along with corresponded half-life (t1/2) are summarized in Table 2. According to these data, most of the antiviral therapeutics have poor solubility which causes failure in the effective treatment of viral diseases. Insufficient or low bioavailability of these antiviral therapeutics because of their low solubility may cause them to be dropped off the pipeline [137–139]. The limitations related to current antiviral therapies can be solved using nano-vehicle based therapeutics by modifying their pharmacodynamic/pharmacokinetic characteristics resulting in the improvement of drug bioavailability, reduction of dose, reduced toxicity and maintenance of the suppression of viral spread [140].

Vaccine development for COVID-19 is based on the following approaches and the main target strategies for successful vaccine fabrication are: averting the ACE2-mediated host uptake, inducing nanobodies against the viral S protein, which can be achieved by means of nanotechnology, inducing an immune response where antigen-loaded nano-vehicles would be a very promising tool, using engineered nanoparticles as vaccine adjuvants to enhance the overall safety and efficacy of the generated immune response, utilizing the intrinsic adjuvanticity of the nanoparticles by activation of inflammasomes which activates the complement system and induces autophagy [141–146].

Combination therapy, a treatment method that is defined as a combination of two or more therapeutic agents, would become a cornerstone to face COVID-19 in the near future. In the absence of approved worldwide treatment against COVID-19, in many countries, instead of using monotherapy, physicians are prescribing multiple medications simultaneously to enhance treatment efficacy as this approach could target crucial pathways in a characteristically synergistic or an additive manner [147]. To this end, nano drug co-delivery systems which can simultaneously load at least two therapeutic agents with not only physicochemical but also pharmacological properties into a propitious nanovehicles could be proposed as an effective alternative option to combat COVID-19. Moreover, can also be considered as an approach that combines the above-mentioned repurposed approaches with other therapies for instance, encapsulation of therapeutic agents into nanovehicles along with surface modification of the drug carrier by targeting moieties.
### Table 1. Nanoparticle-based tools against respiratory viruses.

| Types of substances used for fabrication | Types of virus | Antigen/epitope | Adjuvant | Mean diameter (nm) | Achievements | Ref. |
|----------------------------------------|---------------|-----------------|----------|-------------------|--------------|------|
| Polymeric-based nanostructured materials |               |                 |          |                   |              |      |
| Polyanhydride                           | RSV           | G and F glycoproteins | –       | 200–800           | Vaccinated mice were largely protected against virus replication in the lungs | [69,116] |
| HPMA/NIPAM†                            | RSV           | F protein       | TLR-7/8 agonist | 12–25            | Nanoparticles displayed appropriate antigenicity and elicited high titters of pre-fusion-specific, TH1 isotype anti-RSV F antibodies following vaccination | [117,118] |
| Chitosan                                | IF(H1N1)      | Antigen M2e     | Heat shock protein 70°C | 200–250 | Nanoparticles improved pharmacokinetic profile and enhanced vaccine immunogenicity for inducing antibodies and T cell immunity | [119] |
| Swine IF (H1N2)                         | Killed Swine IF | –              | 571.7    |                   | Intransanal immunization of mice with fabricated nanoparticles directed immune response to a more effective quality profile | [120] |
| IF(H1N1)                                | HA-Split      | –               | 300–350  |                   | Nanovaccine elicited strong cross-reactive mucosal IgA and cellular immune responses in the respiratory tract that resulted in a reduced lung virus titers and nasal viral shedding | [121] |
| IF(H1N1)                                | Antigen of H1N1 | –              | 140      |                   | Nanovaccine reduced morbidity and conferred 100% protective rate to the vaccinated mice against lethal IF virus | [122] |
| IF(H1N1)                                | Hemagglutinin | –               | 100–200  |                   | After three nasal immunizations, the developed nanovaccine induced significantly high levels of serum IgG and mucosal IgA | [123] |
| PLGA‡                                   | Swine IF (H1N2) | Inactivated H1N2 virus | –       | 200–300           | Subcutaneous immunization with fabricated vaccine increased the protective immune responses against IF virus in mice | [124] |
| BPI3V                                   | BPI3V Proteins | –               | 225.4    |                   | Nanovaccine reduced lung pathology and viral antigenic load in the lung sections with clearance of infectious challenge virus in most of the vaccinated pig lung airways | [125] |
| Metal nanoparticles                     |               |                 |          |                   |              |      |
| AU                                      | IF            | Antigen M2e     | CpG      | 12                | Intransanal vaccination of mice with M2e–AuNP conjugates induced M2e-specific IgG serum antibodies and mice vaccinated with soluble CpG as adjuvant in addition to M2e-AuNP were fully protected | [126] |
| Self-assembly proteins and peptide-based nanoparticles |           |                 |          |                   |              |      |
| Q11 peptide§                            | IF(H1N1)      | Antigen M2e     | –        | 15–100            | Vaccination with developed nanoparticles did not only protect mice against homologous challenge of IF PR8 H1N1 virus, but also provide protection against heterologous challenge of highly pathogenic avian IF H7N9 virus | [127] |
| Q11, PAQ11¶ and SIINFEKLQ11#§           | IF(H1N1)      | CD8+ epitope    | –        |                   | Intransanally delivered peptide nanofibers were found to be more immunogenic in comparison to subcutaneous route, thereby it produced greater CD8+ T cell responses in lung-draining lymph nodes, greater numbers of tissue resident T cells and a more rapid tissue resident memory response to IF infection | [128] |
| N of RSV                                | IF(H1N1)      | Antigen M2e     | Montanide™ Gel01 | 15   | Intransal vaccination of nanoparticles induces robust immune responses, including high titters of sera M2e-specific IgG antibodies, T-cell immune responses and mucosal secretory-IgA antibodies in mice | [129] |
| IF(H1N1)                                | Antigen M2e   | –               | 10–100   |                   | Vaccinated mice presented a reduced viral load and minor weight loss and all survived upon challenge with IF virus | [130] |
| RSV                                     | FsII          | Montanide™ Gel01 | –        |                   | Intransal N-FsII immunization elicited anti-F antibodies in mice that were non-neutralizing in vitro and it provided better protection against virus replication especially in the upper airways | [70] |

1N2-hydroxypropyl) methylacrylamide/N-isopropylacrylamide.
2poly(lactic-co-glycolic acid).
3fibrilizing peptide (Ac-QQKFQFOFEQQ-Am).
4(H2N-SSLENFRAYV-SGSG-QQKFQFOFEQQ-Am).
5(H2N-SIINFEKL-SGSG-QQKFQFOFEQQ-Am).
6AuNP: Gold nanoparticle; RSV: Respiratory syncytial virus; TLR: Toll-like receptor; VLP: Viral-like particle.
Table 1. Nanoparticle-based tools against respiratory viruses (cont.).

| Types of substances used for fabrication | Types of virus | Antigen/epitope | Adjuvant | Mean diameter (nm) | Achievements | Ref. |
|-----------------------------------------|----------------|----------------|----------|--------------------|--------------|------|
| Other nanoparticles                      |                |                |          |                    |              |      |
| VLP                                     | RSV            | M1 protein of IF and RSV-F or -G | –        | 40–100             | Intramuscular VLPs vaccination reduced lung viral load and elicited IgG2a dominant RSV-specific IgG antibody responses against RSV-A2 viruses in both serum and lung extract | [131] |
|                                         | IF (H1N1, H3N2, H5N1) | Antigen M2e F protein et G | –        | 60–80             | Mice vaccinated intranasally with VLPs showed viral-specific antibody responses against RSV as well as VLPs conferred enhanced protection against live RSV challenges | [132] |
|                                         | IF(H1N1)        | Hemagglutinin  | –        | 80–120            | Intranasal vaccination of VLP induced broad cross-protection by M2-specific humoral and cellular immune responses | [73] |
| Liposome                                | IF(H1N1)        | M2, HA, NP MP and trehalose 6,6 dimycolate | 10–1000 |                   | Nanoparticles elicited virus-specific memory T-cell responses but not neutralizing antibodies | [133] |

1 N-(2-hydroxypropyl) methacrylamide/N-isopropylacrylamide.
2 poly(lactic-co-glycolic acid).
3 fibrilizing peptide (Ac-QQKFQFQFEQQ-Am).
4(H2N-SSLENFRAYV-SGSG-QQKFQFQFEQQ-Am).
5(H2N-SIINFEKL-SGSG-QQKFQFQFEQQ-Am).
6 AuNP: Gold nanoparticle; RSV: Respiratory syncytial virus; TLR: Toll-like receptor; VLP: Viral-like particle.

Table 2. Water solubility, clinical trial phases, log P and half-life (t1/2) h of existing antiviral molecules against coronavirus 2019.

| Drug                          | Water solubility (mg/ml) | Log P | Half-life (t1/2) h | Recommended dosage | Clinical trial phase(s) |
|-------------------------------|--------------------------|-------|-------------------|--------------------|------------------------|
| Practically insoluble         |                          |       |                   |                    |                        |
| Fingolimod                    | 0.0069                   | 4.06  | 144–216           | 0.5 mg/day         | Phase II               |
| Umifenovir                    | –                        | −4.5  | 17–21             | –                  | Phase IV               |
| Lopinavir                     | –                        | 4.69  | 6.9               | 200 mg/12 h up to 7–10 days | Phase II               |
| Ritonavir                     | –                        | 3.9   | 3–5               | 100 mg/12 h up to 10 days | Phase IV               |
| Very slightly soluble         |                          |       |                   |                    |                        |
| Baricitinib                   | 0.357                    | −1    | 12.5              | 2 mg/day up to 14 days | Phase II, III          |
| Ifenprodil                    | 0.105                    | 3.98  | Not available     | 20 and 40 mg TID   | Phase II, III          |
| Remdesivir                    | 0.339                    | 2.1   | 14, 20            | 200 mg on day 1 followed by 100 mg on days 2–10 | Phase III              |
| Ruxolitinib                   | 0.116                    | 2.48  | 2.8               | 10 mg/12 h         | Phase II, III          |
| Darunavir                     | 0.0668                   | 1.89  | 15                | 400 mg/day up to 5 days | Phase IV               |
| Camostat                      | 0.0626                   | 1.51  | 2.8–3.7           | 400 mg/6 h up to 7 days | Phase II               |
| Hydroxychloroquine            | 0.0175                   | 2.89  | 537.6             | 600 mg/day up to 7 days | Phase II               |
| Chloroquine                   | 0.0175                   | 4.63  | 480–1440          | 250 mg/day up to 10 days | Phase II               |
| Slightly soluble              |                          |       |                   |                    |                        |
| Ribavir                       | 33.20                    | −2.8  | 120–170           | 400 mg/12 h up to 5 days | Phase II               |
| Favipiravir                   | 8.70                     | 0.25  | 2–5.5             | 1800 mg/12 h on day 1 followed by 800 mg/12 h up to 7 days | Phase II, III          |
| Galidesivir                   | 7.40                     | −2.1  | Not available     | iv. infusion every 12 h up to 7 days | Phase I               |
| EIDD-2801                     | 5.77                     | −2    | Not available     | Oral capsul/day up to 5 days | Phase I               |
| Thalidomide                   | 2.55                     | 0.33  | 5–7               | 100 mg/day up to 14 days | Phase II               |
| Emtricitabine                 | 2.00                     | −0.43 | 10                | 200 mg/day up to 60 days | Phase II, III          |
| Tenofovir                     | 1.87                     | 1.25  | 32                | 300 mg/day up to 60 days | Phase II, III          |
| Oseltamivir                   | 0.686                    | 1.16  | 1–3              | 75 mg/12 h up to 14 days | Phase II               |

1 Three-times a day.
2 molnupiravir.
Note: The aforementioned drugs were used to treat COVID-19 – either alone or in combination with other medication(s).
COVID-19: Coronavirus 2019.
One of the bigger challenges in the treatment of COVID-19 is the accumulation of therapeutics at nontargeted or unwanted sites. This could be overwhelmed significantly by applying active targeting of nano-vehicles to direct therapeutics to the intended site of action [79,148]. Furthermore, it is possible to target the intracellular and cellular sites and specific organs including cathepsin binding sites, ACE2 expressing cells and domains of viral S protein which are involved in the pathophysiology of SARS-CoV-2. The release of drugs from nanovehicles in a controlled and sustained manner can provide better patient compliance, minimized side effects and reduced dosage amount and frequency and mitigated risk effects of the viral rebounded during viral infection treatments [149].

In order to end this pandemic, diagnostics could play profound roles, as it is crucial to isolate the confirmed cases of COVID-19 as early as possible to prevent the dissemination [150]. Typically, testing kits rely on either the detection of antibodies (via ELISA) or RNA (via PCR, in which the specimen is taken from the throat or nose of the infected patients) associated with the virus. This approach is based on the interactions between the pathogen surface with a complementary detection strand or ligand which is present in the kit [56]. However, these kits are far from perfect due to the following problems: lack of analytical sensitivity, long response times and false-negative results [37]. To this end, nano-sized materials could potentially instigate highly efficient surface interactions between the analyte and the sensor resulting in rapid, accurate and more reliable detection of the virus [43]. Therefore, in order to shorten the response times to ascertain whether an individual is infected or not, as well as to reduce the burden of disease, nanotechnology could provide faster, more precise, simpler and user-friendly platforms without requiring any highly qualified staff or special facilities.

It has been reported that coronaviruses cannot replicate on any non-living surface such as plastic, fabrics, wood, glass and metal surfaces, but they can remain viable or infectious for several hours to days. Several disinfectants, such as sodium hypochlorite (0.1%), hydrogen peroxide (0.5%) or ethanol (62–71%) are effective at destroying coronaviruses, but it is nearly impossible to continuously sanitize a device surface or contaminated surfaces, since they can be recontaminated. Furthermore, these disinfectants are effective at high concentrations, which can cause environmental and health problems due to their high toxicity. Research into solving the aforementioned problems is already underway, also it is believed that one promising approach to end this pandemic is employing an anti-viral surface coating in which the surface is ought to be non-sticking to the pathogen, repealing the pathogen or self-sanitizing. Recent studies revealed that spike (S) glycoprotein is a key surface protein of coronaviruses, mediating the entrance of the virus into human epithelial cells in the respiratory track by interacting with cell surface receptor ACE2. Hence, as stated above, a wiser solution to face this pandemic is development of a surface coating with a relatively low surface energy value which can repel the S glycoprotein.

A smart multi-functional anti-pathogen coating with ‘anti-adhesion’, ‘contact-killing’ and ‘release-killing’ properties has been already introduced into healthcare settings to fight the increasing threat of infectious diseases. Moreover, an antimicrobial coating solution for almost all surfaces with the aid of nano-actives has been fabricated and the literature has supported them as an anti-viral as well. For example, NANOVA HYGIENE+ as an antimicrobial coating was developed by the incorporation of positively charged silver nanoparticles as bioactive nanoparticles dispersed into binder polymers for coating of surfaces like metals, plastics, fabrics, etc. [151]. In addition, introducing titanium dioxide nanoparticles into a polymeric matrix leading to the generation of a photocatalytic coating (light mediated) can kill and destroy pathogens (viruses) on surfaces upon exposure to light by damaging their membrane. Additionally, to further increase the inhibitory effect of respiratory face masks, nano-actives can also be incorporated into their fabric. These nanomaterials exhibit a great potential as an anti-viral coating against coronaviruses due to their unique properties including intrinsic anti-viral properties such as reactive oxygen species (ROS) generation and photo-dynamic and photo-thermal capabilities.

Coronaviruses can be transmitted through various routes including biofluids, respiratory droplets and coughs [52] and it seems that one auspicious strategy to face this invisible enemy is through preventing its dissemination by routinely applying disinfectants to surrounding surfaces, skin or air. In this regard, different chemical disinfectants such as alcohols, quaternary amines, peroxides and chlorines have been used to tackle the pathogens by means of sterilization and disinfection surfaces and personal protective equipment [53]. Although chemical disinfectants exhibited promising results, their application has been restricted gradually due to several drawbacks such as possible risks to the environment and public health, limited effectiveness over time and 100% viral inhibition is achieved only at high concentration [54,55]. Therefore, inorganic nanoparticles, more specifically metal-based nanomaterials such as titanium dioxide (TiO2), copper (Cu) and silver (Ag) nanoparticles, owing to their persistence and ability to be effective at much lower dosages and inherent broad-spectrum antiviral activities, have been proposed as effective alternatives against newly emerging viruses [56,152]. Based on these results, it can be concluded that nanomedicine
Figure 6. Schematic representation of possible strategies to tackle coronavirus 2019 using nanotechnology.

Based strategies are powerful tools to tackle the COVID-19 pandemic. A schematic representation of possible strategies to tackle COVID-19 using nanotechnology is shown in Figure 6.

Conclusion & future perspective

Global health is confronted with the most dangerous situation regarding the novel SARS-CoV-2, known as the COVID-19 pandemic, affecting people's life in every region and community in the world. Nanotechnology-based medications may play a crucial role in advancing COVID-19 diagnosis, treatment, prevention and vaccine development. Additionally, time is of essence when encountering infectious disease outbreaks and nano-based materials have more of a chance to become available sooner to the public in comparison with other treatment options, since they are not associated with lengthy and strict regulatory affairs that are commonly associated with vaccines. It is necessary to develop broad antiviral spectrum of disinfectants with acceptable efficacy even at low concentrations and shortening response times to ascertain whether an individual is infected or not. Moreover, it is pivotal to overcome problems associated with monotherapy and to reduce the dose of the drug and decrease its adverse effects. Furthermore, development of a surface coating with a relatively low surface energy (which can repel, kill or be anti-adhesive to the pathogens) is a wise solution that can mitigate the burden of diseases at places where the viral load is high. Nano-based materials can take root against the current global public health threat by promoting exactly the type of wide-ranging, integrated approaches that are indispensable to manage and control the COVID-19 outbreak at both the local and international level. Despite the intense studies on the
nanotechnology based tools (polymeric, inorganic self-assembling materials, PBNPs and nanovaccine) to mitigate the COVID-19, there have been some drawbacks such as fibrosis, inflammation, oxidative stress, genotoxicity, immunotoxicity, costly, time-consuming, restriction affairs and potential cell toxicity of these nanoparticles, which are not neglectable in rational design and engineering, remain hazy and this make it very difficult to achieve an effective clinical translation. In the not too distant future, we anticipate that many advancements will be achieved in COVID-19 diagnosis, treatment and therapy using nanotechnology based strategies. It is very likely that nanotechnology-based tools will not only be able to be employed in treatment of COVID-19, but also in a wide range of emerging pathogens. This can be achieved using nanotechnology-based vaccines or monoclonal antibodies which precisely deliver the active agents to targeted tissues as well as providing very rapid detection of these viruses. Finally, the biggest challenge will always remain the possibility of these nanomaterials to achieve clinical translation and the feasibility of a scaled-up production.

Executive summary

- Recently, the new coronavirus 2019 (COVID-19) outbreak, as an emerging infectious disease was first reported in Wuhan, China, has infected millions of people worldwide and has become a global threat.
- Nanomedicine, as a very power tool, can mitigate the burden of disease by providing nanoparticle-based carriers and vaccines.

Nanotechnology-based treatments for COVID-19 infections

- Nano-based therapeutics such as polymeric nanoparticles, self-assembling protein based nanoparticles, peptide-based nanoparticles and inorganic and metallic nanoparticles, owing to their unique features, exhibit a broad range of applications in the medical field, therefore they could be used as promising approaches in COVID-19 treatment.

Role of nanotechnology in vaccine development

- The great merits of vaccine development via nanomaterials are their intrinsic adjuvanticity as well as inducing an immune response where antigen-dependent nano-carriers would be a very promising tool.
- Thereby antigens could be loaded whether inside or on the surface of nanocarriers.

Nanomaterial applications in diagnosing COVID-19

- Metallic and inorganic nanoparticles due to unique physicochemical characteristics could address critical criteria and considerations for developing clinically translational nanosized devises in the rapid diagnosis of COVID-19.

Unsolved concerns & perspectives

- Recombination and mutation could occur in many RNA viruses and it makes the virus more dangerous to humans, also it should be considered as a serious global health threat.
- Nano-based materials, due to their nanosized features, could cause severe problems in lung and respiratory systems and this negative aspect should be considered in rational design of nanoparticles for COVID-19 treatment.

Future possible strategies to tackle COVID-19 by means of nanotechnology

- Design and development of effective therapy against COVID-19 is based on the following strategies.
  - Capability of nanomaterials to bypass the conventional restriction associated with antiviral agents.
  - Combination therapeutics using nano-vehicles.
  - Active targeting by decorating specific (nano) targeting moieties on the surface of nanomaterials.
  - Nano-biosensors for rapid detection.
  - Anti-viral surface coatings by the introduction of nanomaterials within the polymer matrix.
  - Capability of nanomaterials as disinfectant agents, and.
  - Vaccine development using nanomaterials and chemically alter/(re)engineer drugs.

Conclusion & future perspective

- Fibrosis, inflammation, oxidative stress, genotoxicity, immunotoxicity and potential cell toxicity of these nanoparticles are key issues to be solved before reaching patients.

Acknowledgments

The authors are thankful to the Zanjan University of Medical Sciences, Maragheh University of Medical Sciences, The John Paul II Catholic University of Lublin, Drohobyhch Ivan Franko State Pedagogical University, Erciyes University, University of Miami and North-eastern University.

Financial & competing interests disclosure

YN Ertas acknowledges funding support from 2232 International Fellowship for Outstanding Researchers Program of TÜBİTAK (Project No: 118C346). The authors have no other relevant affiliations or financial involvement with any organization or entity.
with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

1. Khan S, Liu J, Xue M. Transmission of SARS-CoV-2, required developments in research and associated public health concerns. Front. Med. 7, 310 (2020).

2. Valenti M, Zmerly H. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease. J. Popul. Ther. Clin. Pharmacol. 27(Suppl. 1), e14–e25 (2020).

3. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39(5), 529–539 (2017).

4. International Committee on Taxonomy of VirusesInternational Committee on Taxonomy of Viruses. Van Regenmortel MHV, Fauquet CM, Bishop DHL. Virus taxonomy: classification and nomenclature of viruses: Seventh report of the International Committee on Taxonomy of Viruses. Academic Press, CA, USA, 395–480 (2000).

5. Weiss SR, Navas-Martín S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69(4), 635–664 (2005).

6. Decaro N, Mari V, Elia G et al. Recombinant canine coronaviruses in dogs. Europe. Emerg. Infect. Dis. 16(1), 41 (2010).

7. Sturman LS, Holmes KV. The molecular biology of coronaviruses. Adv. Virus Res. 28, 35–112 (1983).

8. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J. Clin. Med. 9(4), 1225 (2020).

9. Wu A, Peng Y, Huang B et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27(3), 325–328 (2020).

10. Chan JFW, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223), 514–523 (2020).

11. Paraskevis D, Kostaki EG, Magiorkinis G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol. 79, 104212 (2020).

12. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497–506 (2020).

13. Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270–273 (2020).

14. Huang H, Fan C, Li M et al. COVID-19: a call for physical scientists and engineers. ACS Nano 14(4), 3747–3754 (2020).

15. Lovato A, De Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 99(9), 569–576 (2020).

16. Bai Y, Yao L, Wei T et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 323(14), 1406–1407 (2020).

17. Rahimi H, Salehiabar M, Barsbay M et al. CRISPR systems for COVID-19 diagnosis. ACS Sensors doi:10.1021/acssensors.0c02312 (2021) (Epub online ahead of print).

• Presents contemporary studies on the detection of coronavirus 2019 based on the CRISPR system.

18. Aghari A, Naseri M, Safari H, Saboory E, Parsamanesh N. The novel insight of SARS-CoV-2 molecular biology and pathogenesis and therapeutic options. DNA Cell Biol. 39(10), 1741–1753 (2020).

19. Chauhan DS, Prasad R, Srivastava R, Jaggi M, Chauhan SC, Yallapu MM. Comprehensive review on current interventions, diagnostics, and nanotechnology perspectives against SARS-CoV-2. Bioconj. Chem. 31(9), 2021–2045 (2020).

20. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237–261 (2016).

• Gives an overall on the features and evolution of coronavirus spike proteins.

21. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7(6), 439–450 (2009).

22. Bestle D, Heindl MR, Limburg H et al. TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets. Life Sci Alliance 3(9), e202000786 (2020).

23. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271–280.e8 (2020).

24. De Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv. Virus Res. 64, 165–230 (2005).

25. Chang C-K, Sue SC, Yu TH et al. Modular organization of SARS coronavirus nucleocapsid protein. J. Biomed. Sci. 13(1), 59–72 (2006).

26. Ruch TR, Machamer CE. The coronavirus E protein: assembly and beyond. Viruses 4(3), 363–382 (2012).
27. Siu Y, Troh K, Lo J et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. *J. Virol.* 82(22), 11318–11330 (2008).

28. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. *Virology* 16(1), 1–22 (2019).

29. Neuman BW, Kiss G, Kunding AH et al. A structural analysis of M protein in coronavirus assembly and morphology. *J. Struct. Biol.* 174(1), 11–22 (2011).

30. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. In: *Coronaviruses*. Maier HJ, Bickerton E, Britton P (Eds). Humana Press, NY, USA, 1–23 (2015).

31. Escors D, Ortego J, Lude H, Enjuanes L. The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability. *J. Virol.* 75(3), 1312–1324 (2001).

32. Narayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. *J. Virol.* 74(17), 8127–8134 (2000).

33. Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. Coronavirus envelope (E) protein remains at the site of assembly. *Virology* 415(2), 69–82 (2011).

34. Rashidzadeh H, Salimi M, Sadighian S, Rostamizadeh K, Ramazani A. Nanostructured lipid carriers. *Curr. Drug Deliv.* 18(1), 1–23 (2020).

35. Florindo HF, Kleiner R, Vaskovich-Koubi D. Coronavirus M protein and nucleocapsid interaction in infected cells. *J. Virol.* 74(17), 8127–8134 (2000).

36. Vaculovicova M, Michalek P, Križkova S, Macka M, Adam V. Nanotechnology-based analytical approaches for detection of viruses. *Anal. Methods* 9(16), 2375–2391 (2017).

37. Udugama B, Kadhiresan P, Kozlowski HN et al. Diagnosing COVID-19: the disease and tools for detection. *ACS Nano* 14(4), 3822–3835 (2020).

38. Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: overview and perspectives. *Immune Med.* 16(1), 1–22 (2019).

39. Singh L, Kruger HG, Maguire GE, Govender T, Parboosing R. Therapeutic use of nanotechnology in the treatment of viral infections. *Ther. Adv. Infect. Dis.* 4(4), 105–131 (2017).

40. Weiss C, Carriere M, Fusco L et al. Toward nanotechnology-enabled approaches against COVID-19. *ACS Nano* 14(6), 6383–6406 (2020).

41. Talebian S, Conde J. Why go NANO on COVID-19 pandemic? *Matter* 3(3), 598–601 (2020).

42. Campos EV, Pereira AE, De Oliveira JL et al. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. *J. Nanobiotechnol.* 18(1), 1–23 (2020).

43. Abazari M, Ghaffari A, Rashidzadeh H, Momeni Badeleh S, Maleki Y. Transmission routes of 2019-nCoV and controls in dental practice. *Int. J. Oral Sci.* 12(1), 1–6 (2020).

44. Rashidzadeh H, Salimi M, Sadighian S, Rostamizadeh K, Ramazani A. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nanomedicine* 13(1), 219–230 (2017).

45. Singh L, Kruger HG, Maguire GE, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. *Ther. Adv. Infect. Dis.* 4(4), 105–131 (2017).

46. Weiss C, Carriere M, Fusco L et al. Toward nanotechnology-enabled approaches against COVID-19 pandemic. *ACS Nano* 14(6), 6383–6406 (2020).

47. Talebian S, Conde J. Why go NANO on COVID-19 pandemic? *Matter* 3(3), 598–601 (2020).

48. Campos EV, Pereira AE, De Oliveira JL et al. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. *J. Nanobiotechnol.* 18(1), 1–23 (2020).

49. Abazari M, Ghaffari A, Rashidzadeh H, Momeni Badeleh S, Maleki Y. Current status and future outlook of nano-based systems for burn wound management. *J. Biomed. Mater. Res. B Appl. Biomater.* 108(5), 1934–1952 (2020).

50. Abazari M, Ghaffari A, Rashidzadeh H, Momeni Badeleh S, Maleki Y. A systematic review on classification, identification, and healing process of burn wound healing. *Int. J. Low. Extrem. Wounds* 17(4), 75–85 (2020).

51. Florindo HF, Kleiner R, Vaskovich-Koubi D et al. Immune-mediated approaches against COVID-19. *Nat. Nanotechnol.* 15(8), 630–645 (2020).

52. Vaculovicova M, Michalek P, Križkova S, Macka M, Adam V. Nanotechnology-based analytical approaches for detection of viruses. *Anal. Methods* 9(16), 2375–2391 (2017).

53. Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. Coronavirus envelope (E) protein remains at the site of assembly. *Virology* 415(2), 69–82 (2011).

54. Rashidzadeh H, Salimi M, Sadighian S, Rostamizadeh K, Ramazani A. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nanomedicine* 13(1), 219–230 (2017).

55. Wang J, Shen J, Ye D et al. Nanomaterial-based biosensors for detection of pathogenic virus. *Trends Anal. Chem.* 97, 445–457 (2017).

56. Abazari M, Ghaffari A, Rashidzadeh H, Momeni Badeleh S, Maleki Y. Current status and future outlook of nano-based systems for burn wound management. *J. Biomed. Mater. Res. B Appl. Biomater.* 108(5), 1934–1952 (2020).

57. Rashidzadeh H, Salimi M, Sadighian S, Rostamizadeh K, Ramazani A. In vivo antiplasmodial activity of curcumin-loaded nanostructured lipid carriers. *Carr. Drug Deliv.* 16(10), 923–930 (2019).

58. Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nat. Mater.* 9(7), 572–578 (2010).

59. Keijzer C, Slüter B, Van Der Zee R, Jiskoot W, Van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. *PLoS ONE* 6(11), e26684 (2011).

60. Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature* 534(7607), 396–401 (2016).

61. Li B, Zhang X, Dong Y. Nanoscale platforms for messenger RNA delivery. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 11(2), e1530 (2020).

62. Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nat. Mater.* 9(7), 572–578 (2010).

63. Keijzer C, Slüter B, Van Der Zee R, Jiskoot W, Van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. *PLoS ONE* 6(11), e26684 (2011).

64. Li B, Zhang X, Dong Y. Nanoscale platforms for messenger RNA delivery. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 11(2), e1530 (2020).

65. Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature* 534(7607), 396–401 (2016).

66. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. *Int. J. Oral Sci.* 12(1), 1–6 (2020).

67. Fathizadeh H, Maroufi P, Momen-Heravi M et al. Protection and disinfection policies against SARS-CoV-2 (COVID-19). *Infez. Med.* 28(2), 185–191 (2020).

68. Wang J, Shen J, Ye D et al. Disinfection technology of hospital wastes and wastewaters: suggestions for disinfection strategy during coronavirus disease 2019 (COVID-19) pandemic in China. *Environ. Pollut.* 262, 114665 (2020).
55. Talebian S, Wallace GG, Schroeder A, Stellacci F, Conde J. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nat. Nanotechnol. 15(8), 618–621 (2020).

56. Sportelli MC, Izzi M, Kukushkina EA, et al. Can nanotechnology and materials science help the fight against SARS-CoV-2? Nanomaterials 10(4), 802 (2020).

57. Akbarzadeh A, Kafshdoos L, Razban Z, et al. An overview application of silver nanoparticles in inhibition of herpes simplex virus. Artif. Cells, Nanomed. Biotechnol. 46(2), 263–267 (2018).

58. Rezaei SJT, Sarijloo E, Rashidzadeh H, et al. pH-triggered prodrug micelles for cisplatin delivery: preparation and in vitro/vivo evaluation. React. Funct. Polymers 146, 104399 (2020).

59. Lee C, Hwang AR, Jose L, et al. RAFT/PISA based Ni-NTA polymeric particles for virus-mimetic influenza vaccines. J. Industr. Eng. Chem. 86, 35–38 (2020).

60. Rashidzadeh H, Tabatabaei Rezaei SJ, Zamani S, Sarijloo E, Ramazani A. pH-sensitive curcumin conjugated micelles for tumor triggered drug delivery. J. Biomater. Sci. Polymer Ed. doi:10.1080/09205063.2020.1833815 (2020) (Epub online ahead of print).

61. Haycook CP, Balsamo JA, Glass EB, et al. PEGylated PLGA nanoparticle delivery of eggmanone for T cell modulation: applications in rheumatic autoimmune. Int. J. Nanomed. 15, 1215 (2020).

62. Cohen SA, Kingma PS, Whitsett J, Goldbart R, Traitel T, Kost J. SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant's lung diseases. Int. J. Pharm. 585, 119387 (2020).

63. Aghajanzadeh M, Zamani S, Rashidzadeh H, Rostamizadeh K, Sharafi A, Danafar H. Amphiphilic Y shaped miktoarm star copolymer for anticancer hydrophobic and hydrophilic drugs codelivery: synthesis, characterization, in vitro, and in vivo biocompatibility study. J. Biomed. Mater. Res. Pt A 106(11), 2817–2826 (2018).

64. Amjadi S, Hamishehkar H, Ghorbani M. A novel smart PEGylated gelatin nanoparticle for co-delivery of doxorubicin and betanin: a strategy for enhancing the therapeutic efficacy of chemotheraphy. Mater. Sci. Eng. C 97, 833–841 (2019).

65. Sankarakumar N, Tong YW. Preventing viral infections with polymeric virus catchers: a novel nanotechnological approach to anti-viral therapy. J. Mater. Chem. B 1(15), 2031–2037 (2013).

● Effective example of polymeric nanoparticles in preventing of viral infections.

66. Lin LCW, Huang CY, Yao BY, et al. Vitronemimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus. Adv. Funct. Mater. 29(28), 1807616 (2019).

67. Wang W, Yu X, Li Y, Su Z, Jandt KD, Wei G. Protein-mimetic peptide nanofibers: motif design, self-assembly synthesis, and sequence-specific biomedical applications. Prog. Polymer Sci. 80, 94–124 (2018).

68. Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10, 22 (2019).

● Gives an overview on the main strategies based on nanoparticles for vaccine development against respiratory viruses.

69. Roux X, Dubuquoy C, Durand G, et al. Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PloS ONE 3(3), e706 (2008).

70. Hervé P-L, Deloizy C, Descamps D, et al. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PloS ONE 13(2), 411–420 (2017).

71. Balke I, Zeltins A. Recent advances in the use of plant virus-like particles as vaccines. Viruses 10(4), 802 (2018).

72. Hervé P-L, Deloizy C, Descamps D, et al. An overview application of silver nanoparticles in inhibition of herpes simplex virus. Artif. Cells, Nanomed. Biotechnol. 46(2), 263–267 (2018).

73. Lee YT, Ko EJ, Lee Y, et al. Characterization of the prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2. Biochemistry 47(26), 6802–6808 (2008).

74. McReynolds S, Jiang S, Guo Y, et al. Characterization of the prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2. Biochemistry 47(26), 6802–6808 (2008).

75. Pimentel TA, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 73(1), 53–61 (2009).

76. Han Y, Král L.P. Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 14(4), 5143–5147 (2020).

77. Mansoor F, Earley B, Cassidy JP, Markey B, Doherty S, Welsh MD. Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves. BMC Vet. Res. 11(1), 220 (2015).

78. Maiti D, Zhong J, Zhang Z, et al. Polyoxyomylglrolate (POM) nanoclusters with radiosensitizing and scintillating properties for low dose X-ray inducible radiation-radiodynamic therapy. Nanoscale Horizons 5(1), 109–118 (2020).

79. Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10, 22 (2019).

80. Ahmadian E, Eftekhari A, Kavetsky T, Khoosroushahi AH, Turkyo VA, Khalilov R. Effects of quercetin loaded nanostructured lipid carriers on the paraquat-induced toxicity in human lymphocytes. Pestic. Biochem. Physiol. 167, 104586 (2020).
81. Qiao X, Wang C, Niu Y. N-Benzyl HMTA induced self-assembly of organic-inorganic hybrid materials for efficient photocatalytic degradation of tetracycline. *J. Hazard. Mater.* 391, 122121 (2020).

82. Yilmaz YY, Yalcinkaya EE, Demirkol DO, Timur S. 4-aminothiophenol-intercalated montmorillonite: organic-inorganic hybrid material as an immobilization support for biosensors. *Sens. Actuators B Chem.* 307, 127665 (2020).

83. Kang S, Ahn S, Lee J et al. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. *J. Control. Release* 256, 56–67 (2017).

84. Bastús NG, Sánchez-Tilló E, Pujals S et al. Peptides conjugated to gold nanoparticles induce macrophage activation. *Mol. Immunol.* 46(4), 743–748 (2009).

85. Belmouaddine H, Shi M, Sanche L, Houde D. Tuning the size of gold nanoparticles produced by multiple filamentation of femtosecond laser pulses in aqueous solutions. *Phys. Chem. Chem. Phys.* 20(36), 25403–25413 (2018).

86. Al Shehab S, El Kurdi R, Patra D. Curcumin mediated PEG thiol acid conjugated gold nanoparticles for the determination of melamine. *Microchem. J.* 153, 104382 (2020).

87. Zhang J, Mou L, Jiang X. Surface chemistry of gold nanoparticles for health-related applications. *Chem. Sci.* 11(4), 923–936 (2020).

88. Wang C, Zhu W, Luo Y, Wang BZ. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. *Nanomedicine* 14(4), 1349–1360 (2018).

89. Dykman LA. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. *Expert Rev. Vaccines* 19(5), 465–477 (2020).

**Application of metallic nanoparticles to tackle infectious disease.**

90. Jazayeri MH, Amani H, Pourfatollah AA, Pazoki-Toroudi H, Sedighimoghaddam B. Various methods of gold nanoparticles (GNPs) conjugation to antibodies. *Sens. Biosens. Res.* 9, 17–22 (2016).

91. Cao-Milan R, Liz-Marzan LM. Gold nanoparticle conjugates: recent advances toward clinical applications. *Expert. Opin. Drug Deliv.* 11(5), 741–752 (2014).

92. Marques Neto LM, Kipnis A, Junqueira-Kipnis AP. Role of metallic nanoparticles in vaccinology: implications for infectious disease vaccine development. *Front. Immunol.* 8, 239 (2017).

93. Salazar-González JA, Gonzalez-Ortega O, Rosales-Mendoza S. Gold nanoparticles and vaccine development. *Expert. Rev. Vaccines* 14(9), 1197–1211 (2015).

94. Sekimukai H, Iwata-Yoshikawa N, Fukushi S. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. *Exp. Biol. Med.* 241(1), 33–51 (2015).

95. Li Y, Jin Q, Ding P et al. Gold nanoparticles enhance immune responses in mice against recombinant classical swine fever virus E2 protein. *Biotechnol. Lett.* 42(7), 1169–1180 (2020).

96. Kim J, Yeom M, Lee T et al. Porous gold nanoparticles for attenuating infectivity of influenza A virus. *J. Nanobiotechnology* 18(1), 54 (2020).

97. Slutter B, Bal S, Keijzer C et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. *Vaccine* 28(38), 6282–6291 (2010).

98. Li AV, Moon JJ, Abraham W et al. Generation of effector memory T cell–based mucosal and systemic immunity with pulmonary nanoparticle vaccination. *Sci. Transl. Med.* 5(204), 204ra130–204ra130 (2013).

99. Ballester M, Nembrini C, Dhar N et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. *Vaccine* 29(40), 6959–6966 (2011).

100. Lixin L, Zhijia L, Haolin C et al. A translatable subunit nanovaccine for COVID-19. doi:10.26434/chemrxiv.12301157.v1 (2020) (Preprint).

101. Yang Z-Y, Kong W-P, Huang Y et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 428(6982), 561–564 (2004).

102. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-fidelity coronavirus vaccine protects in an aerosol delivery system against SARS coronavirus challenge. *J. Infect. Dis.* 182, 345–351 (2005).

103. Abbott TR, Dhamdhere G, Liu Y et al. Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza. *Cell* 181(4), 865–876.e12 (2020).

104. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. *Nat. Mater.* 12(11), 967–977 (2013).

105. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. *ACS Nano* 14(10), 12522–12537 (2020).
108. Gao A, Liang H, Shen Q et al. Designing a novel nano-vaccine against SARS-CoV-2. *Nano Biomed. Eng.* 12(4), 321–324 (2020).
109. Pacheco TJ, Da Silva VCM, De Souza DG. Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - *Review. Res. Soc. Dev.* 9(12), e20191211123–e20191211123 (2020).
110. Brito LA, Chan M, Shaw CA et al. A cationic nanoeumulsion for the delivery of next-generation RNA vaccines. *Mol. Ther.* 22(12), 2118–2129 (2014).
111. Banoo S, Bell D, Bousuyl P et al. Evaluation of diagnostic tests for infectious diseases: general principles. *Nat. Rev. Microbiol.* 5(11), S21–S31 (2007).
112. Ai T, Yang Z, Hou H et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology* 296(2), E32–E40 (2020).
113. Fang Y, Zhang H, Xie J et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology* 296(2), E115–E117 (2020).
114. Moitra P, Alfieef M, Dighe K, Frieman M, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. *ACS Nano* 14(6), 7617–7627 (2020).

**Clear example of effective nanoparticles for detection of coronavirus 2019.**

115. Zhu X, Wang X, Han L et al. Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19. *Bioens. Biodelectro.* 166, 112437 (2020).
116. Megill JL, Kelly SM, Kumar P et al. Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf. *Sci. Rep.* 8(1), 1–15 (2018).
117. Ulery BD, Phanse Y, Sinha A, Wannemuehler MJ, Narasimhan B, Bellerie BH. Polymer chemistry influences monocyte uptake of polyanhydride nanoparticle. *Pharm. Res.* 26(3), 683–690 (2009).
118. Francica JR, Lynn GM, Laga R et al. Thermoresponsive polymer nanoparticles co-deliver RSV F trimers with a TLR-7/8 adjuvant. *Bioconjug. Chem.* 27(10), 2372–2385 (2016).
119. Lynn GM, Laga R, Darrah PA et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. *Nat. Biotechnol.* 33(11), 1201 (2015).
120. Dabaghian M, Latifi AM, Tebianian M, Najminejad H, Ebrahimi SM. Nasal vaccination with r4M2e. HSP70c antigen encapsulated in heterologous cell-mediated immune response in pigs. *J. Control. Release* 247, 194–205 (2017).
121. Dhakal S, Renu S, Ghiomire S et al. Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs. *Front. Immunol.* 9, 934 (2018).
122. Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. *AAPS PharmSciTech* 15(2), 317–325 (2014).
123. Liu Q, Zheng X, Zhang C et al. Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration. *J. Med. Virol.* 87(11), 1807–1815 (2015).
124. Okamoto S, Matsuura M, Akagi T et al. Poly (γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. *Vaccine* 27(42), 5896–5905 (2009).
125. Dhakal S, Hiremath J, Bondra K et al. Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. *J. Control. Release* 247, 194–205 (2017).
126. Tao W, Zieme KS, Gill HS. Gold nanoparticle–M2e conjugate coformulated with Cpg induces protective immunity against influenza A virus. *Nanomedicine (Lond.)* 9(2), 237–251 (2014).
127. Wang Q, Zhang Y, Zou P et al. Self-assembly M2e-based peptide nanovaccine confers broad protection against influenza viruses. *Front. Microbiol.* 11, 1961 (2020).
128. Si Y, Wen Y, Kelly SH, Chong AS, Collier JH. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. *J. Control. Release* 282, 120–130 (2018).
129. Qi M, Zhang XE, Sun X et al. Intranasal nanovaccine confers homo- and hetero-subtypic influenza protection. *Small* 14(13), 1703207 (2018).
130. Hervé P-L, Raliou M, Bourdieu C et al. A novel subnucleocapsid nanoplatform for mucosal vaccination against a virus that targets the ectodomain of matrix protein 2. *J. Virol.* 88(1), 325–338 (2014).
131. Quan F-S, Kim Y, Lee S et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. *J. Infect. Dis.* 204(7), 987–995 (2011).
132. Cai M, Wang C, Li Y et al. Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice. *Acta Biochim. Biophys. Sin. (Shanghai)* 49(1), 74–82 (2017).
133. Tai W, Roberts L, Seryshev A et al. Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. *Mucosal Immunol.* 4(2), 197–207 (2011).
134. Pertusa F, Serpi M, McGuigan C. Medicinal chemistry of nucleoside phosphate prodrugs for antiviral therapy. *Antiviral Chem. Chemother.* 22(5), 181–203 (2012).
135. De Clercq E, Field HJ. Antiviral prodrugs—the development of successful prodrug strategies for antiviral chemotherapy. *Br. J. Pharm.* 147(1), 1–11 (2006).

136. Ceccarelli M, Berretta M, Rullo EV, Nunari G, Cacopardo B. Editorial—differences and similarities between severe acute respiratory syndrome (SARS)-CORONAVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? *Eur. Rev. Med. Pharmacol. Sci.* 24, 2781–2783 (2020).

137. Kanikkannan N. Technologies to improve the solubility, dissolution and bioavailability of poorly soluble drugs. *J. Anal. Pharm. Res.* 7(1), 00198 (2018).

138. Sheen P-C, Kim S-I, Petillo JJ, Serajuddin AT. Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans. *J. Pharm. Sci.* 80(7), 712–714 (1991).

139. Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions. *AAPS PharmSciTech* 15(4), 822–833 (2014).

140. Mainardes RM, Diedrich C. The potential role of nanomedicine on COVID-19 therapeutics. *Ther. Del.* 11(7), 411–414 (2020).

141. Hornung V, Bauerfeind F, Halle A *et al.* Silica crystals and aluminium salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat. Immunol.* 9(8), 847 (2008).

142. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. *Nat. Rev. Immunol.* 13(10), 722–737 (2013).

143. Demento SL, Eisenbarth SC, Foellmer HG *et al.* Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. *Vaccine* 27(23), 3013–3021 (2009).

144. Panzarini E, Dini L. Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy? *Mol. Pharm.* 11(8), 2527–2538 (2014).

145. Li H, Li Y, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. *Nat. Nanotechnol.* 6(10), 645–650 (2011).

146. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere−serum interface: implications for stealth nanoparticle engineering. *ACS Nano* 4(11), 6629–6638 (2010).

147. Mokhtari RB, Homayouni TS, Baluch N *et al.* Combination therapy in combating cancer. *Oncotarget* 8(23), 38022 (2017).

148. Pearce AK, O’reilly RK. Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine. *Bioconjug. Chem.* 30(9), 2300–2311 (2019).

149. Kumar AR, Aeila ASS. Sustained release matrix type drug delivery system: an overview. *World. J. Pharm. Pharm. Sci.* 9(1), 470–480 (2019).

150. Cohen J, Kupferschmidt K. Labs scramble to produce new coronavirus diagnostics. *Science* 367(6479), 727 (2020).

151. Ghosh SK. Anti-viral surface coating to prevent spread of novel coronavirus (COVID-19) through touch. *http://www.coatingsworld.com/content-microsite/cw_covid-19/2020-04-15/anti-viral-surface-coating-to-prevent-spread-of-novel-coronavirus-covid-19-through-touch* (2020).

152. Shahzadi S, Zafar N, Sharif R. Antibacterial activity of metallic nanoparticles. In: *Bacterial pathogenesis and antibacterial control*. Kirmusao˘glu S (Ed.). IntechOpen, London, UK, 51–71 (2018).